A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

Advanced Solid Tumor Clinical Trial

Official title:

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FB849 Administered in Subjects With Advanced Solid Tumors Alone and in Combination With Pembrolizumab

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05761223
• Other study ID #: FB849_P101
• Secondary ID: KEYNOTE-F25MK-34
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 9, 2023
• Est. completion date: October 2026

Study information

• Verified date: January 2024
• Source: 1ST Biotherapeutics, Inc.
• Contact: 1STBIO Information center
• Phone: +82-31-895-4677
• Email: info[@]1stbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is the first-in-human, multicenter, open-label Phase I/II study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of FB849 alone and in combination with pembrolizumab in subjects with advanced solid tumors for whom no standard therapy is available.

Description:

The study will be conducted in 4 parts: Phase I dose-escalation and dose-expansion parts with FB849 monotherapy and Phase II dose-escalation and dose-expansion parts of FB849 in combination with pembrolizumab.

The Phase Ia dose-escalation part will use an adaptive study design termed Bayesian optimal interval (BOIN) design to investigate the safety and tolerability of FB849, and determine the maximum tolerated dose (MTD) and preliminary recommended Phase II dose (RP2D) of FB849. A BOIN design is a hybrid of rule-based and model-based design, which has the flexibility of dose escalation and de-escalation and allows more subjects to be enrolled into the doses closest to the target toxicity rate.

The Phase Ib dose expansion of FB849 monotherapy part will be initiated once the preliminary RP2D has been determined in the Phase Ia part to provide assessment of safety and anti-tumor activity of FB849 in subjects with advanced solid tumors. It will evaluate FB849 at the preliminary RP2D. Based on data from the Phase Ia part, an additional dose ≥ 1 dose lower than the preliminary RP2D may be evaluated if needed, as determined by the safety monitoring committee (SMC). Subjects will be enrolled using a Simon's two-stage enrollment. If more than 1 dose level cohort is evaluated, subjects will be randomized to a dose level. For each cohort, an interim analysis will be performed prior to opening the second stage of enrollment in each cohort (Simon's two-stage optimal design).

Phase IIa enrollment will be initiated after Stage 1 of Phase Ib is completed. The selected RP2D from the prior Phase Ib part and a dose level ≥ 1 dose lower than the RP2D of FB849 will be selected by the SMC and will be evaluated in combination with a standard dose of pembrolizumab. Dose escalation will follow a BOIN design, but with at least 6 subjects at each FB849 dose level.

In the Phase IIb part of the study, subjects with Type A cancer, Type B cancer, or Type C cancer will be enrolled in 3 cohorts to evaluate FB849 at the RP2D in combination with a standard dose of pembrolizumab to provide assessments of safety and anti-tumor activity of FB849. Enrollment will follow a Simon's two-stage design enrollment, similar to Phase Ib.

Subjects will be monitored for safety, tolerability, and preliminary efficacy throughout the study. Tumor response will be assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 approximately every 6 weeks (± 3 days) in the first 18 weeks, then every 12 weeks (± 7 days) thereafter until disease progression, using computed tomography or magnetic resonance imaging of the chest, abdomen/pelvis, and if clinically indicated additional assessments eg, craniocerebral imaging, bone scan. Treatment with FB849 will continue until the start of a new anti-cancer treatment, disease progression, subject refusal, unacceptable toxicity, death, lost to follow-up, etc, whichever occurs first. Subjects who discontinue treatment due to other reasons than disease progression will continue with tumor assessments as per protocol until disease progression, death, or starting a new anti-cancer treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 151
• Est. completion date: October 2026
• Est. primary completion date: June 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject should understand, sign, and date the written ICF prior to screening.

• Male or female aged 18 years or older.

• Subjects must have at least 1 measurable target lesion according to RECIST version 1.1.

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

• Life expectancy = 3 months in the opinion of the investigator.

• Adequate organ function and bone marrow function as indicated by the following screening assessments performed within 14 days prior to the first dose of study treatment

Exclusion Criteria:

• Known allergy or hypersensitivity to any component of the study treatment.

• Has a known additional malignancy that is progressing or has required active treatment.

• Has abnormal or inadequately controlled endocrine function.

• Inability to take oral medication or significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption of oral medication.

• Previous anti-cancer therapy, including chemotherapy (chemotherapy with nitrosourea or mitomycin should be at least 6 weeks prior to initiation of study treatment), radiotherapy, molecular targeted therapy, or other investigational drugs received = 4 weeks; endocrine therapy = 2 weeks or = 5-half-lives (whichever is shorter) prior to initiation of study treatment.

Related Conditions & MeSH terms

• Advanced Solid Tumor

Intervention

Drug:
• Phase Ia dose-escalation part of FB849 Monotherapy
At a given level dose once daily
• Phase Ib dose-expansion of FB849 monotherapy
At recommended dose for expansion cohort once daily
• Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab
At recommended dose for expansion cohort once daily in combination with pembrolizumab
• Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)
At recommended dose for expansion cohort once daily in combination with pembrolizumab
• Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)
At recommended dose for expansion cohort once daily in combination with pembrolizumab
• Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)
At recommended dose for expansion cohort once daily in combination with pembrolizumab

Locations

Country	Name	City	State
United States	Mary Crowley Cancer Research Center	Dallas	Texas
United States	Next Oncology Virginia	Fairfax	Virginia
United States	NEXT Oncology San Antonio	San Antonio	Texas
United States	Summit Cancer Centers - Spokane Valley	Spokane	Washington

Sponsors (2)

Lead Sponsor	Collaborator
1ST Biotherapeutics, Inc.	Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the safety and tolerability of FB849 and to identify maximum tolerated dose (MTD)/ recommended Phase II dose (RP2D) and dosing schedule of FB849 in subjects with advanced solid tumors	The MTD is defined to be the highest safe dose with an estimated DLT rate less than 30.	DLT Assessment at the end of Cycle 1(each cycle is 21 days.)
Secondary	To determine the pharmacokinetic parameters such as Peak Plasma Concentration (Cmax) of FB849	The PK parameters should include, where appropriate, area under the concentration-time curve (AUC), maximum observed concentration (Cmax), time to maximum observed concentration (tmax), and apparent terminal elimination half-life (t1/2), apparent total body clearance (CL/F), apparent volume of distribution (Vz/F), Cmax at steady state (Css-max), minimum observed concentration at steady state (Css-min), AUC at steady state (AUCss), accumulation ratio (Rac), amount excretion (Ae), fraction excretion (Fe), renal clearance (CLR).	Blood: Predose, 1, 2, 4, 8, 12, 24 hours postdose at C1D1 and C1D21; predose and 4, 8, and 24 hours postdose at C1D8; predose at C1D15; and predose on C2D1, C4D1, and C6D1, Urine: predose and 0-4 hour, 4-8 hour, 8-12 hour, 12-24 hour post-dose
Secondary	To assess preliminary anti-tumor activity of FB849	Tumor response will be assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 using computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen/pelvis, and additional assessments (e.g., craniocerebral imaging, bone scan) based on clinical indications.	every 6 weeks (± 3 days) in the first 18 weeks, then every 12 weeks (± 7 days) thereafter until disease progression assessed up to approximately 3 years